ERBB2 and neoplasm: In relation to stages of the tumour, 77 and 79% of the patients coexpressing high levels of HER1, HER3 and HER4 (+HER1/+HER3/+HER4) (Table 2) or high levels of HER2, HER3 and HER4 (+HER2/+HER3/+HER4) (Table 3), respectively, correlated with early stage of the tumour (Ta–T1).